
doi: 10.1159/000090644
pmid: 16508331
• Many patients previously classified as 'idiopathic short stature' have Primary IGFD. In some studies, this number is as high as 50%. • For patients with severe Primary IGFD, treatment of choice should be IGF-I, either alone or in combination with IGFBP-3. • For patients with Primary IGFD due to defects of the IGF-I gene, IGF-I (alone) is the treatment of choice. • For patients with milder forms of Primary IGFD, the relative advantages of therapy with IGF-I vs. GH need further evaluation.
Male, Hormone Replacement Therapy, Patient Selection, methods: Hormone Replacement Therapy, drug therapy: Growth Disorders, deficiency: Insulin-Like Growth Factor I, Insulin-Like Growth Factor Binding Protein 3, therapeutic use: Insulin-Like Growth Factor Binding Protein 3, Growth Hormone, Humans, Female, therapeutic use: Growth Hormone, Insulin-Like Growth Factor I, Growth Disorders
Male, Hormone Replacement Therapy, Patient Selection, methods: Hormone Replacement Therapy, drug therapy: Growth Disorders, deficiency: Insulin-Like Growth Factor I, Insulin-Like Growth Factor Binding Protein 3, therapeutic use: Insulin-Like Growth Factor Binding Protein 3, Growth Hormone, Humans, Female, therapeutic use: Growth Hormone, Insulin-Like Growth Factor I, Growth Disorders
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 37 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
